BioNTech (UK) Buy Hold or Sell Recommendation
| 0A3M Stock | USD 113.60 7.06 6.63% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding BioNTech SE is 'Cautious Hold'. The recommendation algorithm takes into account all of BioNTech's available fundamental, technical, and predictive indicators you will find on this site.
Check out BioNTech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as BioNTech and provide practical buy, sell, or hold advice based on investors' constraints. BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
BioNTech |
Execute BioNTech Buy or Sell Advice
The BioNTech recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioNTech SE. Macroaxis does not own or have any residual interests in BioNTech SE or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioNTech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
BioNTech Trading Alerts and Improvement Suggestions
| BioNTech SE had very high historical volatility over the last 90 days | |
| About 65.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: BioNTechs SWOT analysis oncology pipeline fuels stocks potential amid market volatility - Investing.com |
BioNTech Returns Distribution Density
The distribution of BioNTech's historical returns is an attempt to chart the uncertainty of BioNTech's future price movements. The chart of the probability distribution of BioNTech daily returns describes the distribution of returns around its average expected value. We use BioNTech SE price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioNTech returns is essential to provide solid investment advice for BioNTech.
| Mean Return | 0.45 | Value At Risk | -4.48 | Potential Upside | 6.63 | Standard Deviation | 3.91 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioNTech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioNTech Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (5.8M) | (49.8M) | (438.4M) | 62.9M | 81.9M | 86.0M | |
| Change In Cash | 107.6M | 691.1M | 482.5M | 12.1B | (2.4B) | (2.2B) | |
| Net Borrowings | 3.5M | 7.9M | 141.7M | (66.7M) | (76.7M) | (72.9M) | |
| Depreciation | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 192.6M | |
| Capital Expenditures | 38.6M | 66M | 127.5M | 363.3M | 705.5M | 740.8M | |
| Net Income | (179.1M) | 15.2M | 10.3B | 9.4B | 930.3M | 883.8M | |
| End Period Cash Flow | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
| Change To Netincome | 8.2M | 30.2M | 25.7M | 1.3B | 1.4B | 1.5B | |
| Free Cash Flow | (269.6M) | (98.9M) | 735.7M | 13.2B | 4.7B | 3.3B | |
| Other Non Cash Items | 262K | 114.5M | 212.5M | (297.9M) | (1.3B) | (1.2B) |
BioNTech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioNTech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioNTech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioNTech stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.36 | |
β | Beta against Dow Jones | 0.72 | |
σ | Overall volatility | 3.94 | |
Ir | Information ratio | 0.08 |
BioNTech Volatility Alert
BioNTech SE shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure BioNTech's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact BioNTech's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.BioNTech Fundamentals Vs Peers
Comparing BioNTech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioNTech's direct or indirect competition across all of the common fundamentals between BioNTech and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioNTech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioNTech's fundamental indicators could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioNTech to competition |
| Fundamentals | BioNTech | Peer Average |
| Return On Equity | 0.24 | -0.31 |
| Return On Asset | 0.17 | -0.14 |
| Profit Margin | 0.48 % | (1.27) % |
| Operating Margin | 0.64 % | (5.51) % |
| Current Valuation | 9.89 B | 16.62 B |
| Shares Outstanding | 239.77 M | 571.82 M |
| Shares Owned By Insiders | 65.11 % | 10.09 % |
| Shares Owned By Institutions | 17.59 % | 39.21 % |
| Price To Book | 1.36 X | 9.51 X |
| Price To Sales | 3.40 X | 11.42 X |
| Revenue | 3.82 B | 9.43 B |
| Gross Profit | 16.07 B | 27.38 B |
| EBITDA | 5.94 B | 3.9 B |
| Net Income | 930.3 M | 570.98 M |
| Cash And Equivalents | 914.9 M | 2.7 B |
| Cash Per Share | 3.75 X | 5.01 X |
| Total Debt | 28.1 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 2.67 X | 2.16 X |
| Book Value Per Share | 83.02 X | 1.93 K |
| Cash Flow From Operations | 5.37 B | 971.22 M |
| Earnings Per Share | 18.00 X | 3.12 X |
| Price To Earnings To Growth | 0.05 X | 4.89 X |
| Target Price | 219.54 | |
| Number Of Employees | 5.5 K | 18.84 K |
| Beta | 0.24 | -0.15 |
| Market Capitalization | 31.25 B | 19.03 B |
| Total Asset | 23.01 B | 29.47 B |
| Retained Earnings | 19.76 B | 9.33 B |
| Working Capital | 17.46 B | 1.48 B |
| Net Asset | 23.01 B |
BioNTech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioNTech . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BioNTech Buy or Sell Advice
When is the right time to buy or sell BioNTech SE? Buying financial instruments such as BioNTech Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioNTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioNTech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.